Related Experiment Videos
Clopidogrel use in coronary artery disease
Aaron L Baggish1, Marc S Sabatine
1Department of Cardiology, Massachusetts General Hospital, Boston, MA, USA. abaggish@partners.org
Expert Review of Cardiovascular Therapy
|December 27, 2005
Summary
Clopidogrel, an adenosine diphosphate receptor antagonist, effectively inhibits platelet activation. Its benefits are well-established for patients with stable coronary artery disease and acute coronary syndromes.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Platelet activation is key in acute coronary syndromes.
- Clopidogrel is an oral thienopyridine and adenosine diphosphate receptor antagonist.
- It inhibits platelet activation, crucial for cardiovascular events.
Purpose of the Study:
- To review clopidogrel's pharmacology.
- To highlight clopidogrel trial results in acute coronary syndromes.
- To identify areas of uncertainty and future research directions.
Main Methods:
- Review of clopidogrel pharmacology.
- Analysis of clinical trial data in acute coronary syndromes.
- Synthesis of existing literature on clopidogrel efficacy.
Main Results:
- Clopidogrel benefits are established in stable coronary artery disease and acute coronary syndromes.
- The drug's utility has been evaluated in numerous patient trials.
- Evidence supports its role in preventing thrombotic events.
Conclusions:
- Clopidogrel is a vital therapeutic agent for acute coronary syndromes.
- Further research is needed to address remaining uncertainties.
- Optimal use in various clinical settings continues to be explored.